| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $3.8M | +16.6% |
| SG&A Expense | $4.5M | -45.2% |
| Operating Income | -$8.2M | +27.7% |
| Net Income | -$8.2M | +37.0% |
| EPS (Basic) | -$55.21 | -95.4% |
| EPS (Diluted) | -$55.21 | -95.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $5.0M | +178.1% |
| Current Assets | $5.6M | +91.4% |
| Total Assets | $5.7M | +94.1% |
| Current Liabilities | $1.6M | -39.3% |
| Total Liabilities | $1.7M | -36.7% |
| Stockholders' Equity | $4.0M | +1456.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.6M | +4.2% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | $11.8M | +9.6% |
| Free Cash Flow | -$8.6M | +4.3% |